COSCIENS Biopharma Inc.
CSCIF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.39M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.39 Million |
|---|---|
| Enterprise Value | $3.07 Million |
| Earnings per Share | $-29.97 |
| Beta | 1.9 |
| Outstanding Shares | 1,047,172 |
Return
| Return on Equity | -32.16% |
|---|---|
| Return on Assets | -25.32% |
| Return on Invested Capital | -27.13% |
Valuation & Multiples
| P/E Ratio | -0.47 |
|---|---|
| PEG | 0.51 |
| Price to Sales | 0.87 |
| Price to Book Ratio | 0.44 |
| Enterprise Value to Revenue | 0.37 |
| Enterprise Value to EBIT | -0.68 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.64 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-2.00
Consensus analyst estimateRevenue Estimate
$615,000
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Aeterna Zentaris Inc.
28 employees
CEO: Klaus Paulini
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved ora...